IGFBP4 and cardiovascular disorder: PAPP-A-derived IGFBP-4 proteolytic fragments are considered to be diagnostic and prognostic biomarkers of various cardiovascular diseases (CVDs), such as acute coronary syndrome (ACS) [18], acute heart failure [19], and ischemia [20].